Antiretroviral treatment response of HIV‐infected children after prevention of mother‐to‐child transmission in West Africa. Issue 2 (2nd June 2014)

• Record Type: Journal Article
• Authors: Ndondoki, Camille; Dicko, Fatoumata; Coffie, Patrick Ahuatchi; Eboua, Tanoh Kassi; Ekouevi, Didier Koumavi; Kouadio, Kouakou; Aka, Addi Edmond; Malateste, Karen; Dabis, François; Amani‐Bosse, Clarisse; Toure, Pety; Leroy, Valériane
• Is Part Of: Journal of the International AIDS Society. Volume 17:Issue 2 (2014)Supplement 1
• Page Start: n/a
• Page End: n/a
• Publication Date: 2014-06-02
• Subjects: PMTCT -- HIV -- children -- antiretroviral efficiency -- West Africa; AIDS (Disease) -- Periodicals; HIV infections -- Periodicals; 616.9792005
• DOI: 10.7448/IAS.17.1.18737
• Languages: English
• ISSNs: 1758-2652

Abstract

Abstract : Introduction: We assessed the rate of treatment failure of HIV‐infected children after 12 months on antiretroviral treatment (ART) in the Paediatric IeDEA West African Collaboration according to their perinatal exposure to antiretroviral drugs for preventing mother‐to‐child transmission (PMTCT). Methods: A retrospective cohort study in children younger than five years at ART initiation between 2004 and 2009 was nested within the pWADA cohort, in Bamako‐Mali and Abidjan‐Côte d'Ivoire. Data on PMTCT exposure were collected through a direct review of children's medical records. The 12‐month Kaplan‐Meier survival without treatment failure (clinical or immunological) was estimated and their baseline factors studied using a Cox model analysis. Clinical failure was defined as the appearance or reappearance of WHO clinical stage 3 or 4 events or any death occurring within the first 12 months of ART. Immunological failure was defined according to the 2006 World Health Organization age‐related immunological thresholds for severe immunodeficiency. Results: Among the 1035 eligible children, PMTCT exposure was only documented for 353 children (34.1%) and remained unknown for 682 (65.9%). Among children with a documented PMTCT exposure, 73 (20.7%) were PMTCT exposed, of whom 61.0% were initiated on a protease inhibitor‐based regimen, and 280 (79.3%) were PMTCT unexposed. At 12 months on ART, the survival without treatment failure was 40.6% in the PMTCT‐exposed group, 25.2% in the unexposed group and 18.5% in the children with unknown exposure status ( p =0.002). In univariate analysis, treatment failure was significantly higher in children unexposed (HR 1.4; 95% CI: 1.0–1.9) and with unknown PMTCT exposure (HR 1.5; 95% CI: 1.2–2.1) rather than children PMTCT‐exposed ( p =0.01). In the adjusted analysis, treatment failure was not significantly associated with PMTCT exposure ( p =0.15) but was associated with immunodeficiency (aHR 1.6; 95% CI: 1.4–1.9; p =0.001), AIDS clinical events (aHR 1.4; 95% CI: 1.0–1.9; p =0.02) at ART initiation and receiving care in Mali compared to Côte d'Ivoire (aHR 1.2; 95% CI: 1.0–1.4; p= 0.04). Conclusions: Despite a low data quality, PMTCT‐exposed West African children did not have a poorer 12‐month response to ART than others. Immunodeficiency and AIDS events at ART initiation remain the main predictors associated with treatment failure in this operational context.